It's his annual appeal. Mad Money host Jim Cramer wants you to place a couple shares of this stock in the stockings.» Read More
Pavel Molchanov, Raymond James, discusses the production of solar panels and weighs in on SolarCity's acquisition of Silevo.
Andrea James, Dougherty and Company vice president, weighs in on battery supply and how Elon Musk's Gigafactory will disrupt the industry. The FM crew trades the stock.
The best way to trade current market volatility and inflation, with the "Fast Money" crew.
Rising tensions in Iraq are giving investors anxiety. Is this the trigger for a correction? NYSE floor trader Kenny Polcari weighs in.
MacNeil Curry, head of global technical strategy at Bank of America Merrill Lynch, says it's time to sell against the recent strength in copper. With CNBC's Jackie DeAngelis and the Futures Now Traders.
The case against copper and the outlook for industrial metals. Trading copper now, with MacNeil Curry, Bank of America Merrill Lynch, CNBC's Jackie DeAngelis and the Futures Now Traders.
Marc Faber, editor and publisher of the Gloom, Boom & Doom Report, still thinks the Fed is painting itself into a corner, with CNBC's Jackie DeAngelis and the Futures Now Traders.
Is there a Fed shocker ahead? The next move for rates, with CNBC's Jackie DeAngelis and the Futures Now Traders.
Marc Faber, the editor and publisher of the Gloom, Boom & Doom Report, explains why gold's decline from its highs can be blamed on the financial press, with CNBC's Jackie DeAngelis and the Futures Now Traders.
The Fed meeting begins. What Marc Faber, The Gloom, Boom & Doom Report, likes now and where he sees the market headed. With CNBC's Jackie DeAngelis and the Futures Now Traders, Jim Iuorio and Jeff Kilburg, both from the CME.
FMHR trader Stephanie Link is very encouraged by industrial production data in the U.S. She explains her investment strategy for the second half of the year.
Disappointing economic data have only added to concerns, CNBC's Jim Cramer says.
GW Pharmaceuticals is developing effective treatments based on chemical cannabinoids found in marijuana to treat seizures. CNBC's Jim Cramer looks at reports of promising results from its drug Epidiolex.
"It's the animal-spirited stock of this moment," CNBC's Jim Cramer says.
Jim Cramer explains what to watch ahead of the open, including an upgrade for Netflix.
CEO Howard Schultz just made a clever move that should drive shareholder value much further over the long-run.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
The Netherlands may be a small country, but if you’re an investor, Jim Cramer says there’s a big reason to like it.
In celebration of the World Cup, Mad Money host Jim Cramer kicks off his week-long World Cup series with his favorite stock play from the Netherlands.
If anyone hates high taxes, it’s Jim Cramer. And he’s always looking for new ways to do something about them.